| Assessment Status | Rapid Review Complete |
| HTA ID | 25068 |
| Drug | Mirikizumab |
| Brand | Omvoh® |
| Indication | Mirikizumab (Omvoh®) for adult patients with moderate to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. |
| Assessment Process | |
| Rapid review commissioned | 01/12/2025 |
| Rapid review completed | 18/12/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that mirikizumab not be considered for reimbursement for this indication at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.